Cerdelga Approved for Gaucher Disease
WEDNESDAY, Aug. 20, 2014 (HealthDay News) -- Cerdelga (eliglustat) has been approved by the U.S. Food and Drug Administration to treat type 1 Gaucher disease, a rare inherited disorder caused by the body's insufficient production of a key enzyme.
Latest MedicineNet News
Lack of the enzyme glucocerebrosidase causes fatty deposits in the spleen, liver and bone marrow. Symptoms include liver and spleen enlargement, anemia, low blood platelets and bone problems, the FDA said in a news release.
Gaucher affects about 6,000 people in the United States. Cerdelga is a gelatin capsule that's designed to slow the body's production of abnormal fatty deposits.
Cerdelga was evaluated in clinical studies involving 199 people with type 1 Gaucher disease. The most common side effects were fatigue, headache, nausea, diarrhea, and pain of the back, arms and legs, and upper abdomen.
Cerdelga is produced by Genzyme, based in Cambridge, Mass.
-- Scott Roberts
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions